TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04521400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Interferon-beta 1a
Description: Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
Study: NCT03494387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Antioxidants versus placebo
Study: NCT02635269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar
Description: 10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
Study: NCT04524468

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Conventional 2-D transthoracic echocardiography was performed to all patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Conventional 2-D transthoracic echocardiography was performed to all patients
Study: NCT01409356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + exercise
Description: Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
Study: NCT04392765

Intervention type: DEVICE
Group type: OTHER
Intervention: eXciteOSA
Description: eXciteOSA transoral neurostimulation device
Study: NCT02127424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV targeted screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current practice
Study: NCT01297959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-101 Solution 300 GU/ml
Description: 8 mL of E-101 Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution matched to E-101
Study: NCT03062969

Intervention type: PROCEDURE
Intervention: Cleavage stage biopsy group
Description: * intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer

Intervention type: PROCEDURE
Intervention: Trophectoderm biopsy group
Description: * ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer
Study: NCT02650869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Normal breast milk will be given as part of standard care
Study: NCT01285583

Intervention type: DRUG
Group type: OTHER
Intervention: TRO19622
Description: 2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
Study: NCT04414267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
Study: NCT02535910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Subjects are asked to consume a breakfast rich in 20 µg vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH) D3
Description: Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects are asked to consume a breakfast without vitamin D
Study: NCT03818672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550 MG BID
Study: NCT02389972

Intervention type: DRUG
Intervention: Dasatinib
Study: NCT03932604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial sensing On mode
Description: Single lead VDD-ICD programmed as atrial sensing On mode.
Study: NCT01751438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Systemic Therapy (BST)
Description: Group 1 will continue to receive best systemic therapy (BST).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Systemic Therapy (BST) + Surgery or Radiation Therapy
Description: Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call/Email
Description: Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call/Email
Description: Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
Study: NCT00265889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 480 mcg beginning day +5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 480 mcg beginning day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg IV over 2 hours x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg IV over 2 hours x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: autologous-autologous tandem hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: autologous-autologous tandem hematopoietic stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiation therapy
Study: NCT03089918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-JNJ-63779586
Description: Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-JNJ-63779586
Description: Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
Study: NCT00572741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B12
Description: Methylcobalamin Dose: 75 μg/kg every 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folate
Description: Folinic acid: Dose: 400 µg twice a day (BID)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B complex
Description: B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: Vitamin C 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cod liver oil
Description: Cod liver oil 1/2 teaspoon

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral complex
Description: Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnitine
Description: Acetyl L-Carnitine Dose: 250 mg
Study: NCT03195933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cortisol
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cortisol
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
Study: NCT00696709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V212
Description: 0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
Study: NCT00071617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth-Nominated Support Team
Study: NCT03288116

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimplug imaging and contrast and sensitivity test
Description: examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimplug imaging and contrast and sensitivity test
Description: examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimplug imaging and contrast and sensitivity test
Description: examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
Study: NCT02622854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: see arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: see arm description
Study: NCT02122133

Intervention type: DEVICE
Intervention: PC 400

Intervention type: DEVICE
Intervention: PC 400
Study: NCT03490513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole (1 mg/day)
Description: Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
Study: NCT05069090

Intervention type: BEHAVIORAL
Intervention: Lockdown and other social distancing measures
Description: During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).

Intervention type: BEHAVIORAL
Intervention: Lockdown and other social distancing measures
Description: During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
Study: NCT02767258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LACRIBELL®
Description: Hypromellose and dextran based eyedrop, used in the treatment of dry eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIDISIC® GEL
Description: Carbomer based gel, used in the treatment of dry eye.
Study: NCT00951275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Description: As prescribed
Study: NCT01460940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
Study: NCT00318357

Intervention type: DEVICE
Intervention: Continuation of CRT
Description: Implantation of CRT device and medical treatment according normal hospital routine.

Intervention type: DEVICE
Intervention: Upgrade to CRT
Description: Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
Study: NCT03138148

Intervention type: OTHER
Intervention: Routine mechanical ventilation
Description: Routine mechanical ventilation in PICU amid children with acute respiratory failure

Intervention type: OTHER
Intervention: Routine mechanical ventilation
Description: Routine mechanical ventilation in PICU amid children with acute respiratory failure
Study: NCT04510805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextDose (nextdose.org)
Description: NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose.
Study: NCT00778765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Gabapentin Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Gabapentin Capsules
Study: NCT01550458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mibefradil
Description: 25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
Study: NCT01695564

Intervention type: DEVICE
Intervention: LARIAT LAA
Description: The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.

Intervention type: DEVICE
Intervention: WATCHMAN
Description: The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
Study: NCT00363519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT04530292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention by a pediatric nurse at the child's home
Description: The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families.
Study: NCT03285139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
Study: NCT02883738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tremor
Description: evaluation of the intensity of the tremor
Study: NCT04396145

Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective Visual Vertical
Description: All subjects will have Virtual SVV before and after the operation
Study: NCT03254680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
Study: NCT03680755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for dental anxiety
Description: Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for dental anxiety
Description: Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
Study: NCT01257906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL
Description: Topical Gel applied in the evening for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZIANA®
Description: Topical Gel applied in the evening for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Topical Gel applied in the evening for 84 days.
Study: NCT03657277

Intervention type: DEVICE
Group type: OTHER
Intervention: Micropatch
Description: Each micropatch contains 50 tiny projections (800 um in length)
Study: NCT02693743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Study: NCT01825213

Intervention type: DEVICE
Intervention: Multispectral CT of the liver
Description: Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
Study: NCT02878473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor Liver Transplantation
Description: Deceased donor orthotopic liver transplantation
Study: NCT02106611

Intervention type: OTHER
Intervention: Clinical Assessment
Description: HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.

Intervention type: PROCEDURE
Intervention: Stress cardiac MRI
Description: Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.

Intervention type: PROCEDURE
Intervention: Stress echocardiogram
Description: Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.